SteelPeak Wealth LLC Has $37.88 Million Holdings in Amgen Inc. $AMGN

SteelPeak Wealth LLC increased its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 28.1% in the 4th quarter, Holdings Channel.com reports. The institutional investor owned 115,728 shares of the medical research company’s stock after acquiring an additional 25,389 shares during the period. Amgen accounts for 1.2% of SteelPeak Wealth LLC’s holdings, making the stock its 20th largest position. SteelPeak Wealth LLC’s holdings in Amgen were worth $37,879,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also bought and sold shares of the stock. Brighton Jones LLC lifted its holdings in shares of Amgen by 23.5% during the fourth quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after acquiring an additional 5,226 shares during the period. Sivia Capital Partners LLC grew its holdings in shares of Amgen by 10.6% in the 2nd quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock worth $331,000 after purchasing an additional 114 shares during the last quarter. Schnieders Capital Management LLC. grew its holdings in shares of Amgen by 29.3% in the 2nd quarter. Schnieders Capital Management LLC. now owns 25,859 shares of the medical research company’s stock worth $7,220,000 after purchasing an additional 5,853 shares during the last quarter. Arrowstreet Capital Limited Partnership acquired a new stake in shares of Amgen during the 2nd quarter worth about $59,836,000. Finally, Groupe la Francaise acquired a new stake in shares of Amgen during the 2nd quarter worth about $222,000. Institutional investors and hedge funds own 76.50% of the company’s stock.

Amgen Stock Performance

Shares of NASDAQ:AMGN opened at $347.94 on Friday. The company has a current ratio of 1.14, a quick ratio of 0.90 and a debt-to-equity ratio of 5.78. Amgen Inc. has a 1-year low of $261.43 and a 1-year high of $391.29. The stock has a market capitalization of $187.56 billion, a P/E ratio of 24.45, a P/E/G ratio of 3.45 and a beta of 0.47. The business has a 50-day moving average price of $363.65 and a two-hundred day moving average price of $332.36.

Amgen (NASDAQ:AMGN) last issued its earnings results on Tuesday, February 3rd. The medical research company reported $5.29 EPS for the quarter, beating the consensus estimate of $4.76 by $0.53. The company had revenue of $9.87 billion during the quarter, compared to analysts’ expectations of $9.46 billion. Amgen had a net margin of 20.98% and a return on equity of 148.37%. The business’s revenue for the quarter was up 8.6% compared to the same quarter last year. During the same quarter in the previous year, the company posted $5.31 EPS. Amgen has set its FY 2026 guidance at 21.600-23.000 EPS. Equities analysts predict that Amgen Inc. will post 20.62 earnings per share for the current year.

Amgen Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Friday, June 5th. Investors of record on Friday, May 15th will be issued a $2.52 dividend. This represents a $10.08 dividend on an annualized basis and a yield of 2.9%. The ex-dividend date is Friday, May 15th. Amgen’s dividend payout ratio is currently 70.84%.

Wall Street Analysts Forecast Growth

A number of equities analysts have commented on AMGN shares. TD Cowen restated a “buy” rating on shares of Amgen in a research report on Wednesday, February 4th. Cantor Fitzgerald raised their price objective on shares of Amgen from $315.00 to $350.00 and gave the stock a “neutral” rating in a report on Wednesday, February 4th. Citigroup lifted their target price on shares of Amgen from $315.00 to $345.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Truist Financial boosted their target price on Amgen from $318.00 to $319.00 and gave the stock a “hold” rating in a report on Thursday, January 8th. Finally, Deutsche Bank Aktiengesellschaft increased their price target on Amgen from $285.00 to $295.00 and gave the stock a “hold” rating in a research report on Thursday, February 5th. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, thirteen have issued a Hold rating and two have given a Sell rating to the company. According to MarketBeat, Amgen presently has a consensus rating of “Hold” and a consensus target price of $354.60.

Amgen Company Profile

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.